{"id":"W4409587015","doi":"10.1111/ene.70110","title":"The Results of <scp>ADVANCE</scp>‐<scp>CIDP IVIG</scp> Trial: Intravenous Immunoglobulin 10% Therapy With <scp>GAMMAGARD LIQUID</scp>/Kiovig for Treatment of Relapse in Chronic Inflammatory Demyelinating Polyradiculoneuropathy","year":2025,"lang":"en","type":"article","venue":"European Journal of Neurology","topic":"Peripheral Neuropathies and Disorders","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto; University Health Network","funders":"Takeda Development Center Americas","keywords":"Medicine; Polyradiculoneuropathy; Placebo; Internal medicine; Chronic inflammatory demyelinating polyneuropathy; Clinical endpoint; Multifocal motor neuropathy; Confidence interval; Randomized controlled trial; Antibody; Immunology; Guillain-Barre syndrome","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002009107,0.0006057984,0.001402942,0.0004814681,0.0002290388,0.00003801597,0.0006791772,0.0001473176,0.000002391358],"category_scores_gemma":[0.00481557,0.0004113883,0.0005313041,0.0006306922,0.0006160427,0.0001594813,0.0001206468,0.0007914602,0.000005484347],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001532504,"about_ca_system_score_gemma":0.0008266133,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001651315,"about_ca_topic_score_gemma":0.00004700019,"domain_scores_codex":[0.9934971,0.001936832,0.00249933,0.0006147012,0.0005087626,0.0009432937],"domain_scores_gemma":[0.9922471,0.004019202,0.002188755,0.000796219,0.00052235,0.0002263462],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","study_design_scores_codex":[0.305737,0.01158438,0.008413986,0.001566099,0.004152835,0.02334274,0.02915509,0.02308311,0.3863037,0.001092767,0.02376024,0.1818081],"study_design_scores_gemma":[0.1686212,0.1851716,0.02842661,0.0006145578,0.0004665895,0.001374706,0.001617143,0.0005110197,0.01135645,0.0001417984,0.6015612,0.0001370313],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9817587,0.01226405,0.0002122326,0.000833349,0.0009059452,0.001402569,0.00002900057,0.00004776152,0.002546413],"genre_scores_gemma":[0.9819037,0.01468237,0.0002422166,0.0008989916,0.0005930924,0.00003286892,0.00001210351,0.0001710295,0.001463623],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.577801,"threshold_uncertainty_score":0.9998338,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01288040415486335,"score_gpt":0.2555853554341349,"score_spread":0.2427049512792716,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}